Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 9/20 | 0.43 |
| ▸ | ESR1 | P03372 | 6/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7789806 | 1.00 | ESR2 (0.43) | ESR2ESR1GRM2 | |
| SCHEMBL1888940 | 0.86 | ESR2 (0.42) | ESR2ESR1GRM2 | |
| SCHEMBL7782050 | 0.86 | ESR2 (0.42) | ESR2ESR1GRM2 | |
| SCHEMBL7789801 | 0.86 | ESR2 (0.41) | ESR2ESR1GRM2 | |
| SCHEMBL1888520 | 0.86 | ESR2 (0.41) | ESR2ESR1GRM2 | |
| SCHEMBL7787597 | 0.85 | ESR2 (0.45) | ESR2ESR1GRM2 | |
| SCHEMBL1905793 | 0.85 | ESR2 (0.45) | ESR2ESR1GRM2 | |
| SCHEMBL7782046 | 0.80 | ESR2 (0.41) | ESR2ESR1GRM2 | |
| SCHEMBL7791087 | 0.80 | ESR2 (0.48) | ESR2ESR1GRM2 | |
| SCHEMBL7789804 | 0.80 | ESR2 (0.41) | ESR2ESR1GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130189246-A1 | TREATMENT OF OPHTHALMIC CONDITIONS WITH FLUORENONE DERIVATIVES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2013-07-25 | — | — | US | claimed |
| EP-2501227-A1 | TREATMENT OF OPHTHALMIC CONDITIONS WITH FLUORENONE DERIVATIVES | The Trustees of Columbia University in the City of New York (US) | 2012-09-26 | — | — | EP | claimed |
| WO-2011059881-A1 | TREATMENT OF OPHTHALMIC CONDITIONS WITH FLUORENONE DERIVATIVES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2011-05-19 | — | — | WO | claimed |
| US-6251898-B1 | Medical use of fluorenone derivatives for treating and preventing brain and spinal injury | QUESTCOR PHARMACEUTICALS, INC. | 2001-06-26 | — | — | US | claimed |
| WO-2001014334-A1 | FLUORENONE COMPOUNDS WITH MODIFIED 7-POSITION SUBSTITUENTS FOR TREATING AND PREVENTING BRAIN AND SPINAL INJURY | QUESTCOR PHARMACEUTICALS, INC. (US) | 2001-03-01 | — | — | WO | claimed |
| US-20130189246-A1 | TREATMENT OF OPHTHALMIC CONDITIONS WITH FLUORENONE DERIVATIVES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2013-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130189246-A1 | TREATMENT OF OPHTHALMIC CONDITIONS WITH FLUORENONE DERIVATIVES | ALDH1A2, GLI2, MMP1 | ESR2 389/4885ESR1 2644/4885GRM2 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.